Lv51
1050 积分 2020-11-11 加入
Proactive Approaches to cGMP Compliance: Insights and Key Takeaways from USFDA Warning Letters to Pharmaceutical Industries Between 2019 and 2024
1小时前
待确认
A Retrospective Analysis of FDA Warning Letters Issued For Biologics From 2010 To 2025
1小时前
已完结
Establishment of Limit of In Vitro Cell Age (LIVCA) for Biologics Manufacturing Process
27天前
已完结
Analysis of virus clearance for biotechnology manufacturing processes from early to late phase development
3个月前
已完结
Ultra scale‐down prediction using microwell technology of the industrial scale clarification characteristics by centrifugation of mammalian cell broths
3个月前
已完结
Analysis of virus clearance for biotechnology manufacturing processes from early to late phase development
3个月前
已完结
Glycan Profiles of FDA-Approved Therapeutic Antibodies: Insights from Regulatory Submissions
6个月前
已完结
Methods for Estimating the Probability of Clonality in Cell Line Development
7个月前
已完结
A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment
7个月前
已完结
Manufacturing innovation is essential for monoclonal antibody affordability and access
1年前
已完结
皖公网安备34019202002308
